within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A05A_BileTherapy.A05AX06_Elafibranor;

model Elafibranor
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 3.944444444444444e-06,
    adminDuration = 600,
    adminMass = 120 / 1000000,
    adminCount = 1,
    Vd = 0.118,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.011333333333333334,
    Tlag = 15.0,
    Vdp = 0.405,
    k12 = 1.0111111111111111e-05,
    k21 = 1.0111111111111111e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Elafibranor</td></tr><tr><td>ATC code:</td><td>A05AX06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>120</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>118</td><td>L</td></tr>
    <tr><td>clearance:</td><td>14.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta agonist developed for the treatment of metabolic diseases, chiefly nonalcoholic steatohepatitis (NASH). It has been investigated in clinical trials but is not approved for clinical use as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects after oral administration.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A05AX06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Elafibranor;
